MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042)
Conditions: Cytomegalovirus Infection; Cytomegalovirus Disease Interventions: Drug: Letermovir tablet; Drug: Letermovir IV Sponsor: Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cytomegalovirus | Japan Health | Kidney Transplant | Kidney Transplantation | Research | Transplant Surgery | Transplants | Urology & Nephrology